Skip to main content

Table 1 Summary of Patient and Study Characteristics of 209 Studies Included in our Systematic Review

From: Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis

CharacteristicNumber of Studies (%)
Age, mean (years)
  < 707 (3.3)
 70–79·9116 (55.5)
  ≥ 8068 (32.5)
 Not Reported18 (8.6)
% Women
 0–4931 (14.8)
 50–100165 (78.9)
 Not Reported13 (6.2)
Type of Dementia
 Multiple (e.g. AD + VaD)50 (23.9)
 AD110 (52.6)
 VaD10 (4.8)
 Othera9 (4.3)
 Not Reported30 (14.4)
Severity of Dementia
 Mild2 (1)
 Mild/Moderate67 (32.1)
 Mild/Moderate/Severe36 (17.2)
 Moderate5 (2.4)
 Moderate/Severe24 (11.5)
 Severe6 (2.9)
 Not Reported69 (33)
Study Design
 RCT148 (70.8)
 Cohort Study52 (24.9)
 Case-Control Study5 (2.4)
 Pairwise Meta-Analysis of RCTs2 (1)
 Other Non-Randomized Study2 (1)
Setting
 Clinic/Community65 (31.1)
 Hospital7 (3.3)
 Nursing home/Assisted Living45 (21.5)
 Multiple Settings22 (10.5)
 Not Reported70 (33.5)
Sample Size (No. of patients)
  < 20064 (30.6)
 201–50063 (30.1)
  > 50081 (38.8)
 Not Reported1 (0.5)
Duration of Intervention, weeks
  < 1365 (31.1)
 13–3078 (37.3)
  > 3057 (27.2)
 Not Reported9 (4.3)
  1. Abbreviations: AD Alzheimer’s dementia, % percentage, RCT randomized trial, VaD vascular dementia
  2. aOther includes Lewy body dementia, Parkinson’s disease dementia, and frontotemporal dementia